GLK-321 for Demodex Blepharitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called GLK-321 for individuals with Demodex blepharitis, an eye condition caused by tiny mites that lead to red, itchy, and inflamed eyelids. Researchers aim to assess the safety and effectiveness of different doses of GLK-321 compared to a placebo (a substance with no therapeutic effect). Participants will receive either a low, mid, or high dose of GLK-321 or a placebo. Candidates may qualify for this trial if they show signs of Demodex blepharitis in at least one eye and do not have eczema or dermatitis around the eyes. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot use lid hygiene products within 14 days before the trial starts.
Is there any evidence suggesting that GLK-321 is likely to be safe for humans?
Research shows that GLK-321 is undergoing safety testing for treating Demodex blepharitis, an eyelid inflammation caused by mites. Studies have examined patients using different doses of GLK-321, either twice or once daily. So far, these studies have reported no major safety issues.
The treatment appears well-tolerated, and the research aims to identify the safest and most effective dose. However, as this treatment remains experimental, ongoing trials are closely monitoring its safety. Participants should understand that while early results are promising, the treatment is still under evaluation.1234Why do researchers think this study treatment might be promising?
Researchers are excited about GLK-321 for treating Demodex blepharitis because it offers a novel approach compared to existing treatments like tea tree oil or ivermectin. Unlike these standard options, GLK-321 is being tested in multiple doses and frequencies, potentially offering more flexibility and effectiveness in treatment. This drug works by targeting the root cause of the condition, the Demodex mites, with a new active ingredient that might provide faster and more sustained relief. Additionally, the different dosing options, including low, mid, and high doses administered either once or twice daily, could allow for more personalized treatment plans based on individual patient needs.
What evidence suggests that GLK-321 might be an effective treatment for Demodex blepharitis?
Research has shown that GLK-321 yields promising results in combating Demodex mites, tiny parasites linked to Demodex blepharitis. In lab tests, GLK-321 killed these mites more effectively at higher doses. This trial will evaluate different dosing regimens of GLK-321—low, mid, and high doses—to assess its effectiveness in reducing the primary cause of Demodex blepharitis. Although direct evidence from human studies is limited, the mechanism of GLK-321 offers hope for managing this condition by directly targeting the mites. Early signs are encouraging, but further research is needed to confirm these findings in humans.12345
Who Is on the Research Team?
Study Director, MD
Principal Investigator
Glaukos Corporation
Are You a Good Fit for This Trial?
This trial is for individuals with signs of Demodex blepharitis in at least one eye and who have a corrected vision of 20/80 or better. It's not suitable for those who don't meet the visual acuity requirement.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive GLK-321 or placebo for Demodex blepharitis, with doses administered either once or twice daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- GLK-321
Trial Overview
The study tests various doses of GLK-321, given twice daily (BID) or once daily (QD), against a placebo to see which is safest and most effective for treating Demodex blepharitis.
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Placebo Group
Mid dose of GLK-321 administered twice daily (BID) to both eyes
Low dose of GLK-321 administered twice daily (BID) to both eyes
High dose of GLK-321 administered once daily (QD) to both eyes
High dose of GLK-321 administered twice daily (BID) to both eyes
Placebo administered twice daily (BID) to both eyes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Glaukos Corporation
Lead Sponsor
Thomas Burns
Glaukos Corporation
Chief Executive Officer since 2002
B.A. from Yale University
Dr. Tomas Navratil
Glaukos Corporation
Chief Medical Officer since 2022
MD from Harvard Medical School
Citations
Study Details | NCT07400965 | Randomized, Placebo ...
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and ...
Dose Dependent ex vivo Demodicidal Activity of GLK-321 on ...
Conclusions : Dose-dependent elimination of Demodex mites was demonstrated at doses up to 1% for GLK-321 in an ex vivo demodicidal assay, supporting its ...
GLK-321 for Demodex Blepharitis
This trial is for individuals with signs of Demodex blepharitis in at least one eye and who have a corrected vision of 20/80 or better. It's not suitable for ...
4.
ctv.veeva.com
ctv.veeva.com/study/randomized-placebo-controlled-trial-evaluating-the-safety-and-efficacy-of-glk-321-in-subjects-withRandomized, Placebo-controlled Trial Evaluating the Safety ...
Randomized, Placebo-controlled Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis ... Data sourced from ...
Pharmacotherapy of Demodex-Associated Blepharitis - PMC
In the study by Choi et al., the efficacy of topical ivermectin 1%, used once a week for 15 min over approximately 15 weeks, in conjunction with ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.